Fig. 2From: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine compared with 23-valent pneumococcal polysaccharide vaccine among adults in a Norwegian settingTornado diagram showing the 12 input parameters with the highest impact on the incremental cost-effectiveness ratioNote: NBP: Non-bacteraemic pneumoniaBack to article page